PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Epithelial Ovarian CancerOvarian CancerOvarian Cancer Stage IIIOvarian Cancer Stage IV
Interventions
DRUG

Niraparib

"Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Yonsei University

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Takeda

INDUSTRY

lead

Seoul National University Hospital

OTHER